Given the emerging problems associated with IM monotherapy and other BCR-ABL inhibitors, our preclinical in vitro and in vivo data warrant further investigation of low-toxicity CRM1 inhibitors as a novel therapeutic alternative for refractory CML. Here, XPO1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.